1 Department of Internal Medicine, Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque New Mexico, United States of America.
2 Department of Physiology, University of California-San Francisco, San Francisco, California, United States of America.
3 Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
4 Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
5 Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
6 Department of Pharmacology, Miller School of Medicine, Center for Computational Science, University of Miami, Miami, Florida, United States of America.
7 Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
8 Department of Pathology, Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.
9 Department of Microbiology and Immunology, UCSF Diabetes Center, University of California-San Francisco, San Francisco, California, United States of America.
This Formal Comment responds to a recent Meta-Research Article by identifying initiatives that are already in place for funding risky exploratory research that illuminate mysteries of the dark genome.